Novartis is a multinational pharmaceutical company based in Basel, Switzerland. Established in 1996, it was formed through a merger between Swiss companies Ciba-Geigy and Sandoz. The headquarters of Novartis is located in Basel, Switzerland, known as Novartis Campus.

The campus includes research laboratories, manufacturing facilities, and office buildings. It is one of the largest pharmaceutical research centers in the world. Novartis offers a wide range of healthcare products and services.

The company operates in four main segments: Innovative Medicines, Sandoz, Alcon, and Corporate Activities. Innovative Medicines is the largest segment, focusing on developing and commercializing innovative treatments in various therapeutic areas such as oncology, cardiovascular, immunology, and neuroscience. Sandoz is the generic medicines division, supplying affordable medicines across the globe.

Alcon, the eye care division, offers products related to eye health, including surgical devices and vision care solutions. Novartis has a strong global presence with operations in more than 150 countries. The company has numerous subsidiaries, joint ventures, and partnerships worldwide.

Notable subsidiaries include AveXis, acquired in 2018, which focuses on gene therapy for rare genetic diseases; and Precision Medicine, a joint venture with Pfizer, aimed at advancing cancer treatments. Novartis has strategic collaborations with leading research institutions and academic partners to fuel innovation and drug development. In terms of market position, Novartis is one of the largest pharmaceutical companies globally.

In 2020, the company reported net sales of over $48 billion. Novartis competes with other major pharmaceutical companies such as Pfizer, Johnson & Johnson, and Roche. The company's commitment to research and development has resulted in significant achievements, including the successful development of drugs like Gleevec for leukemia and Lucentis for age-related macular degeneration.

Novartis continually evolves its product lineup and business strategy to meet the changing healthcare landscape. It focuses on breakthrough innovations, expanding its pipeline, and increasing access to healthcare globally. The company aims to drive sustainable growth by harnessing advances in science, technology, and digital capabilities.

As of the latest updates, Novartis remains at the forefront of pharmaceutical research and development. It continues to invest in cutting-edge therapies and technologies, including gene and cell therapies. Novartis is dedicated to addressing unmet medical needs and improving patient outcomes worldwide